| Field | Row 1 |
|---|---|
| adsh | 0001628280-25-022761 |
| cik | 1830214 |
| name | GINKGO BIOWORKS HOLDINGS, INC. |
| sic | 2836 |
| countryba | US |
| stprba | MA |
| cityba | BOSTON |
| zipba | 02210 |
| bas1 | 27 DRYDOCK AVENUE |
| bas2 | 8TH FLOOR |
| baph | (877) 442-5362 |
| countryma | US |
| stprma | MA |
| cityma | BOSTON |
| zipma | 02210 |
| mas1 | 27 DRYDOCK AVENUE |
| mas2 | 8TH FLOOR |
| countryinc | US |
| stprinc | DE |
| ein | 872652913 |
| former | SOARING EAGLE ACQUISITION CORP. |
| changed | 20210210 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250506 |
| accepted | 2025-05-06 17:04:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | dna-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-022761 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -850000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Common Stock Shares Outstanding | 54365785.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Accounts Payable Current | 11267000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Additional Paid In Capital | 6555416000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High | 1302000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cash And Cash Equivalents At Carrying Value | 840440000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Common Stock Shares Outstanding | 42696585.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022761 | 20241231 | Common Stock Value | 5000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Contract With Customer Liability Noncurrent | 98783000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Earnings Per Share Basic | -1.6800 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | General And Administrative Expense | 8050000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -165880000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Income Tax Expense Benefit | 88000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Contract With Customer Liability | -12471000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Liabilities Current | 107266000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Marketable Securities | 204502000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Operating Expenses | 215946000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Income Loss | -5185000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -3035000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Other Noncash Income Expense | -149000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Other Nonoperating Income Expense | 12122000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20250331 | Other Nonoperating Income Expense | -1901000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20250331 | Other Operating Income Expense Net | -4289000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Payment For Contingent Consideration Liability Financing Activities | 621000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Proceeds From Stock Options Exercised | 70000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 10055000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Biomedit; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 139000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Other Equity Investee; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Settlement Of Contingent Consideration Value Restricted Stock | 0.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -5837557000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20241231 | Accounts Payable Current | 14169000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20231231 | Cash And Cash Equivalents At Carrying Value | 944073000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Common Stock Shares Outstanding | 8669200.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022761 | 20250331 | Common Stock Shares Outstanding | 3000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class C; | ||
| 0001628280-25-022761 | 20241231 | Contract With Customer Liability Current | 27710000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Contract With Customer Liability Current | 33653000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Contract With Customer Liability Noncurrent | 64786000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20240331 | Cost Of Goods And Services Sold | 9202000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Debt Securities Available For Sale Unrealized Gain Loss | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Earnings Per Share Basic | -3.3100 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Fair Value Option Changes In Fair Value Gain Loss1 | -5285000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Gain Loss On Investments | -2544000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | General And Administrative Expense | 70287000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Income Tax Expense Benefit | 31000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Operating Lease Liability | -4790000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Other Noncurrent Liabilities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Intangible Assets Net Excluding Goodwill | 68756000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Interest Income Expense Net | 11711000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Liabilities And Stockholders Equity | 1377449000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Net Cash Provided By Used In Investing Activities | -12110000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Expenses | 137286000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Operating Lease Right Of Use Asset | 394435000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Other Liabilities Noncurrent | 16576000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Other Operating Income Expense Net | 2015000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Payments To Acquire Property Plant And Equipment | 7622000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Proceeds From Stock Options Exercised | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Research And Development Expense | 70923000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 27889000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 27889000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Cell Engineering Revenue; | ||
| 0001628280-25-022761 | 20240331 | Share Based Compensation | 42397000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Value Acquisitions | 15876000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Additional Paid In Capital | 6576786000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Assets | 1377449000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Cash And Cash Equivalents At Carrying Value | 312420000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 605743000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -102371000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Common Stock Shares Outstanding | 3000000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class C; | ||
| 0001628280-25-022761 | 20250331 | Cost Of Goods And Services Sold | 7957000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | Debt Securities Available For Sale Unrealized Gain Loss | 107000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Equity Securities Fv Ni And Without Readily Determinable Fair Value | 48704000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Fair Value Adjustment Of Warrants | -940000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Fair Value Adjustment Of Warrants | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Finance Lease Principal Payments | 207000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Gain Loss On Investments And Income Loss From Equity Method Investments | -2544000.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Other Accounts Payable And Accrued Liabilities | 10871000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Other Noncurrent Liabilities | 2773000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -462000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Intangible Assets Net Excluding Goodwill | 72510000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Income Loss | -36773000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering And Biosecurity Segments; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022761 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 849000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Profit Loss | -165911000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20250331 | Profit Loss | -90957000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20250331 | Property Plant And Equipment Net | 197828000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Research And Development Expense | 136457000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Research And Development Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | Restricted Cash | 42985000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Restructuring Costs And Asset Impairment Charges | 5273000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 59000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Allonnia; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 38230000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Cell Engineering Revenue; | ||
| 0001628280-25-022761 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1097152000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -5456439000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1806000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -850000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6576786000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Shares Acquisitions | 328321.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Shares Acquisitions | 31127.0000 | shares | 1 | us-gaap/2024 | Award Type= Restricted Stock; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Value Share Based Compensation Forfeited | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 54241619.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Accounts Receivable Net Current | 21857000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Accrued Liabilities And Other Liabilities | 65387000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -1806000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cost Of Goods And Services Sold | 9202000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | Depreciation And Amortization | 15366000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Fair Value Option Changes In Fair Value Gain Loss1 | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | General And Administrative Expense | 18027000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Other Noncurrent Assets | 707000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Increase Decrease Right Of Use Assets | 0.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease Right Of Use Assets | -3675000.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20250331 | Interest Income Expense Net | 6081000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Marketable Securities | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Net Cash Provided By Used In Operating Activities | -89259000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Noncash In Process Research And Development | 0.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 5637000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Payments To Acquire Available For Sale Securities Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Research And Development Expense | 120000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | Research And Development Expense | 48670000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20241231 | Restricted Cash | 44171000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Restructuring Costs And Asset Impairment Charges | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 37944000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 147000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Ayana; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 369000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Genomatica; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 10055000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Service; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 48318000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 7583000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Biomedit; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Share Based Compensation | 20431000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6445255000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Shares Share Based Compensation | 454756.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Value Acquisitions | 15876000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Comprehensive Income Net Of Tax | -168946000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Accounts Receivable Net | 877000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-022761 | 20250331 | Common Stock Shares Outstanding | 8622896.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class B; | ||
| 0001628280-25-022761 | 20241231 | Contract With Customer Liability Current | 795000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20241231 | Contract With Customer Liability Noncurrent | 72260000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Contract With Customer Liability Noncurrent | 80378000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Cost Of Goods And Services Sold | 4090000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001628280-25-022761 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -157000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | General And Administrative Expense | 38244000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Operating Lease Liability | -4097000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Other Noncurrent Assets | 167000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -1154000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Liabilities | 661391000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Liabilities | 646036000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Liabilities And Stockholders Equity | 1293463000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Income Loss | -88968000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Lease Right Of Use Asset | 383394000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 956000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Other Nonoperating Income Expense | -1901000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 5400000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Preferred Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Retained Earnings Accumulated Deficit | -5837557000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Share Based Compensation | 40782000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Share Based Compensation | 20800000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1484000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 647427000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Value Share Based Compensation Forfeited | 529000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Share Based Compensation Forfeited | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Share Based Compensation Forfeited | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 50133366.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Accounts Receivable Net | 586000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Accounts Receivable Net Current | 26293000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Accrued Liabilities And Other Liabilities | 70747000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Assets Current | 564534000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-022761 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Common Stock Shares Outstanding | 54698246.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Comprehensive Income Net Of Tax | -90001000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cost Of Goods And Services Sold | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product And Service Other; | ||
| 0001628280-25-022761 | 20250331 | Earnings Per Share Diluted | -1.6800 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Equity Securities Fv Ni And Without Readily Determinable Fair Value | 32173000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Liabilities Current | 115667000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Net Cash Provided By Used In Financing Activities | -845000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Net Cash Provided By Used In Financing Activities | -207000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Operating Income Loss | -92253000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 7379000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Other Assets Noncurrent | 55336000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -3035000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Other Noncash Income Expense | 442000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Payment For Contingent Consideration Liability Financing Activities | 900000.0000 | USD | 1 | us-gaap/2024 | Award Type= Restricted Stock; | ||
| 0001628280-25-022761 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Preferred Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Property Plant And Equipment Net | 203720000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Restructuring Costs And Asset Impairment Charges | 0.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20250331 | Restructuring Costs And Asset Impairment Charges | 5273000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20250331 | Retained Earnings Accumulated Deficit | -5928514000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 19000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Motif; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 38230000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 10088000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Service; | ||
| 0001628280-25-022761 | 20240331 | Settlement Of Contingent Consideration Value Restricted Stock | 1877000.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20240331 | Settlement Of Contingent Consideration Value Restricted Stock | 1877000.0000 | USD | 1 | 0001628280-25-022761 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -5290528000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1551000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6555416000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Share Based Compensation Forfeited | 0.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 50111460.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 54241619.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 40782000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 40782000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 20431000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 20431000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High | 926000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 989584000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 887213000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 355405000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -250338000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20231231 | Common Stock Shares Outstanding | 50032873.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Contract With Customer Liability Current | 391000.0000 | USD | 0 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Cost Of Goods And Services Sold | 3121000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20240331 | Depreciation And Amortization | 12869000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20250331 | Depreciation And Amortization | 15366000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Corporate Non Segment; | ||
| 0001628280-25-022761 | 20240331 | Finance Lease Principal Payments | 294000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Gain Loss On Investments | -3693000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | General And Administrative Expense | 11951000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | General And Administrative Expense | 49043000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | General And Administrative Expense | 0.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Zymergen; | ||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Contract With Customer Liability | -2912000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Other Accounts Payable And Accrued Liabilities | 6419000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Net Cash Provided By Used In Investing Activities | -198684000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Operating Income Loss | -178002000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Operating Lease Liability Noncurrent | 438766000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Operating Lease Liability Noncurrent | 434561000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Other Comprehensive Income Loss Net Of Tax | -3035000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20250331 | Other Liabilities Noncurrent | 15430000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Payments For Proceeds From Other Investing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Payments For Proceeds From Other Investing Activities | -120000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Payments To Acquire Available For Sale Securities Debt | 191182000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Payments To Acquire Property Plant And Equipment | 6710000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Prepaid Expense And Other Assets Current | 18729000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Profit Loss | -90957000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Research And Development Expense | 81898000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20231231 | Restricted Cash | 45511000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 733000.0000 | USD | 1 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 274000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Genomatica; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Motif; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Other Equity Investee; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 8098000.0000 | USD | 1 | us-gaap/2024 | Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6386191000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 716058000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Shares Share Based Compensation | 332461.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Assets | 1293463000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Assets Current | 602744000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20241231 | Cash And Cash Equivalents At Carrying Value | 561572000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Common Stock Shares Outstanding | 50840607.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20241231 | Common Stock Shares Outstanding | 54365785.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Common Stock Shares Outstanding | 43075350.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022761 | 20250331 | Common Stock Shares Outstanding | 54698246.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Common Stock Value | 5000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Cost Of Goods And Services Sold | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20250331 | Cost Of Goods And Services Sold | 7223000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Depreciation And Amortization | 12869000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Earnings Per Share Diluted | -3.3200 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 74000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Gain Loss On Investments And Income Loss From Equity Method Investments | -3693000.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -90869000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Increase Decrease In Accounts Receivable | 6770000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Increase Decrease In Accounts Receivable | 4693000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Net Cash Provided By Used In Operating Activities | -51521000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Noncash In Process Research And Development | 16816000.0000 | USD | 1 | 0001628280-25-022761 | |||
| 0001628280-25-022761 | 20240331 | Operating Income Loss | -11218000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20240331 | Operating Income Loss | -103471000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering And Biosecurity Segments; Consolidation Items= Operating Segments; | ||
| 0001628280-25-022761 | 20250331 | Operating Income Loss | -31588000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Cell Engineering Segment; | ||
| 0001628280-25-022761 | 20250331 | Other Assets Noncurrent | 46778000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Other Comprehensive Income Loss Net Of Tax | 956000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001628280-25-022761 | 20240331 | Other Nonoperating Income Expense | 12122000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Payment For Contingent Consideration Liability Financing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Prepaid Expense And Other Assets Current | 20442000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Profit Loss | -165911000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Restricted Cash | 46773000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 10088000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Biosecurity Segment; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Allonnia; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 240000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Ayana; Related Party Transactions By Related Party= Related Party; | ||
| 0001628280-25-022761 | 20240331 | Settlement Of Contingent Consideration Shares Restricted Stock | 24657.0000 | shares | 1 | 0001628280-25-022761 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 987270000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-022761 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -5928514000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Acquisitions | 939000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Acquisitions | 328321.0000 | USD | 1 | us-gaap/2024 | Class Of Stock= Common Class A; | ||
| 0001628280-25-022761 | 20250331 | Stock Issued During Period Value Acquisitions | 939000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-022761 | 20240331 | Stock Issued During Period Value Share Based Compensation Forfeited | 529000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Noncurrent Assets | Amount of increase (decrease) in noncurrent assets classified as other. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Depreciation And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization, Nonproduction | The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Increase Decrease In Contract With Customer Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Contract with Customer, Liability | Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. |
| Gain Loss On Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Investments | Amount of realized and unrealized gain (loss) on investment. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High | us-gaap/2024 | 0 | 0 | monetary | D | C | Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High | This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Accounts Receivable Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. |
| Accrued Liabilities And Other Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities and Other Liabilities | Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Settlement Of Contingent Consideration Shares Restricted Stock | 0001628280-25-022761 | 1 | 0 | shares | D | Settlement Of Contingent Consideration, Shares, Restricted Stock | Settlement Of Contingent Consideration, Shares, Restricted Stock | |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Payments For Proceeds From Other Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments for (Proceeds from) Other Investing Activities | Amount of cash (inflow) outflow from investing activities classified as other. |
| Restructuring Costs And Asset Impairment Charges | us-gaap/2024 | 0 | 0 | monetary | D | D | Restructuring Costs and Asset Impairment Charges | Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. |
| Settlement Of Contingent Consideration Value Restricted Stock | 0001628280-25-022761 | 1 | 0 | monetary | D | C | Settlement Of Contingent Consideration, Value, Restricted Stock | Settlement Of Contingent Consideration, Value, Restricted Stock |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Finance Lease Principal Payments | us-gaap/2024 | 0 | 0 | monetary | D | C | Finance Lease, Principal Payments | Amount of cash outflow for principal payment on finance lease. |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. |
| Payments To Acquire Available For Sale Securities Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Debt Securities, Available-for-Sale | Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Other Operating Income Expense Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Operating Income (Expense), Net | The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | I | D | Marketable Securities | Amount of investment in marketable security. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Stock Issued During Period Value Acquisitions | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Acquisitions | Value of stock issued pursuant to acquisitions during the period. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Fair Value Option Changes In Fair Value Gain Loss1 | us-gaap/2024 | 0 | 0 | monetary | D | C | Fair Value, Option, Changes in Fair Value, Gain (Loss) | For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Interest Income Expense Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Income (Expense), Operating | Amount of interest income (expense) classified as operating. |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Gain Loss On Investments And Income Loss From Equity Method Investments | 0001628280-25-022761 | 1 | 0 | monetary | D | C | Gain (Loss) On Investments And Income (Loss) From Equity Method Investments | Gain (Loss) On Investments And Income (Loss) From Equity Method Investments |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Restricted Cash | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash | Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Noncash In Process Research And Development | 0001628280-25-022761 | 1 | 0 | monetary | D | D | Noncash In Process Research And Development | Noncash In Process Research And Development |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Debt Securities Available For Sale Unrealized Gain Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Debt Securities, Available-for-Sale, Unrealized Gain (Loss) | Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Contract With Customer Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Noncurrent | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. |
| Equity Securities Fv Ni And Without Readily Determinable Fair Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Equity Securities, FV-NI and without Readily Determinable Fair Value | Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value. |
| Fair Value Adjustment Of Warrants | us-gaap/2024 | 0 | 0 | monetary | D | D | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Stock Issued During Period Value Share Based Compensation Forfeited | us-gaap/2024 | 0 | 0 | monetary | D | D | Shares Issued, Value, Share-Based Payment Arrangement, Forfeited | Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Contract With Customer Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment for Contingent Consideration Liability, Financing Activities | Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease Right Of Use Assets | 0001628280-25-022761 | 1 | 0 | monetary | D | C | Increase (Decrease) Right of Use Assets | Increase (Decrease) Right of Use Assets |
| Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Noncurrent Liabilities | Amount of increase (decrease) in noncurrent operating liabilities classified as other. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Stock Issued During Period Shares Acquisitions | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Acquisitions | Number of shares of stock issued during the period pursuant to acquisitions. | |
| Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture | Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). | |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-022761 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001628280-25-022761 | 2 | 4 | BS | 0 | H | Marketable Securities | us-gaap/2024 | Marketable securities | 0 |
| 0001628280-25-022761 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0001628280-25-022761 | 2 | 6 | BS | 0 | H | Accounts Receivable Net | us-gaap/2024 | Accounts receivable - related parties | 0 |
| 0001628280-25-022761 | 2 | 7 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001628280-25-022761 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001628280-25-022761 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property, plant and equipment, net | 0 |
| 0001628280-25-022761 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right-of-use assets | 0 |
| 0001628280-25-022761 | 2 | 11 | BS | 0 | H | Equity Securities Fv Ni And Without Readily Determinable Fair Value | us-gaap/2024 | Investments | 0 |
| 0001628280-25-022761 | 2 | 12 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0001628280-25-022761 | 2 | 13 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other non-current assets | 0 |
| 0001628280-25-022761 | 2 | 14 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001628280-25-022761 | 2 | 17 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001628280-25-022761 | 2 | 18 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2024 | Deferred revenue (includes $391 and $795 from related parties) | 0 |
| 0001628280-25-022761 | 2 | 19 | BS | 0 | H | Accrued Liabilities And Other Liabilities | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0001628280-25-022761 | 2 | 20 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001628280-25-022761 | 2 | 22 | BS | 0 | H | Contract With Customer Liability Noncurrent | us-gaap/2024 | Deferred revenue, net of current portion (includes $64,786 and $72,260 from related parties) | 0 |
| 0001628280-25-022761 | 2 | 23 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liabilities, non-current | 0 |
| 0001628280-25-022761 | 2 | 24 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other non-current liabilities | 0 |
| 0001628280-25-022761 | 2 | 25 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001628280-25-022761 | 2 | 26 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 10) | 0 |
| 0001628280-25-022761 | 2 | 28 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | 0 |
| 0001628280-25-022761 | 2 | 29 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.0001 par value (Note 8) | 0 |
| 0001628280-25-022761 | 2 | 30 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001628280-25-022761 | 2 | 31 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001628280-25-022761 | 2 | 32 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0001628280-25-022761 | 2 | 33 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total stockholders equity | 0 |
| 0001628280-25-022761 | 2 | 34 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity | 0 |
| 0001628280-25-022761 | 3 | 6 | BS | 1 | H | Contract With Customer Liability Current | us-gaap/2024 | Deferred revenue, related party | 0 |
| 0001628280-25-022761 | 3 | 7 | BS | 1 | H | Contract With Customer Liability Noncurrent | us-gaap/2024 | Deferred revenue, net of current portion, from related parties | 0 |
| 0001628280-25-022761 | 3 | 8 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001628280-25-022761 | 3 | 9 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, authorized (in shares) | 0 |
| 0001628280-25-022761 | 3 | 10 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, issued (in shares) | 0 |
| 0001628280-25-022761 | 3 | 11 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001628280-25-022761 | 3 | 12 | BS | 1 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable - related parties | 0 |
| 0001628280-25-022761 | 3 | 13 | BS | 1 | H | Marketable Securities | us-gaap/2024 | Marketable securities | 0 |
| 0001628280-25-022761 | 4 | 9 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenue | 0 |
| 0001628280-25-022761 | 4 | 11 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of Biosecurity revenue | 0 |
| 0001628280-25-022761 | 4 | 12 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001628280-25-022761 | 4 | 13 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0001628280-25-022761 | 4 | 14 | IS | 0 | H | Restructuring Costs And Asset Impairment Charges | us-gaap/2024 | Restructuring charges | 0 |
| 0001628280-25-022761 | 4 | 15 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001628280-25-022761 | 4 | 16 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0001628280-25-022761 | 4 | 18 | IS | 0 | H | Interest Income Expense Net | us-gaap/2024 | Interest income, net | 0 |
| 0001628280-25-022761 | 4 | 19 | IS | 0 | H | Gain Loss On Investments | us-gaap/2024 | Loss on investments | 0 |
| 0001628280-25-022761 | 4 | 20 | IS | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liabilities | 1 |
| 0001628280-25-022761 | 4 | 21 | IS | 0 | H | Other Operating Income Expense Net | us-gaap/2024 | Other income (expense), net | 0 |
| 0001628280-25-022761 | 4 | 22 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Total other income (expense) | 0 |
| 0001628280-25-022761 | 4 | 23 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Loss before income taxes | 0 |
| 0001628280-25-022761 | 4 | 24 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense | 0 |
| 0001628280-25-022761 | 4 | 25 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022761 | 4 | 26 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per share, basic (in dollars per share) | 0 |
| 0001628280-25-022761 | 4 | 27 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per share, diluted (in dollars per share) | 0 |
| 0001628280-25-022761 | 4 | 29 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic (in shares) | 0 |
| 0001628280-25-022761 | 4 | 35 | IS | 0 | H | Debt Securities Available For Sale Unrealized Gain Loss | us-gaap/2024 | Debt Securities, Available-for-Sale, Unrealized Gain (Loss) | 0 |
| 0001628280-25-022761 | 4 | 36 | IS | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Total other comprehensive (loss) income | 0 |
| 0001628280-25-022761 | 4 | 37 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive loss | 0 |
| 0001628280-25-022761 | 5 | 10 | IS | 1 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenue | 0 |
| 0001628280-25-022761 | 5 | 11 | IS | 1 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of Biosecurity revenue | 0 |
| 0001628280-25-022761 | 6 | 10 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001628280-25-022761 | 6 | 11 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Beginning balance | 0 |
| 0001628280-25-022761 | 6 | 12 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation | us-gaap/2024 | Issuance of common stock upon exercise or vesting of equity awards (in shares) | 0 |
| 0001628280-25-022761 | 6 | 13 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation Forfeited | us-gaap/2024 | Issuance of common stock upon exercise or vesting of equity awards | 0 |
| 0001628280-25-022761 | 6 | 14 | EQ | 0 | H | Settlement Of Contingent Consideration Shares Restricted Stock | 0001628280-25-022761 | Settlement of contingent consideration (in shares) | 0 |
| 0001628280-25-022761 | 6 | 15 | EQ | 0 | H | Settlement Of Contingent Consideration Value Restricted Stock | 0001628280-25-022761 | Settlement of contingent consideration | 0 |
| 0001628280-25-022761 | 6 | 16 | EQ | 0 | H | Stock Issued During Period Shares Acquisitions | us-gaap/2024 | Issuance of common stock for asset acquisition (in shares) | 0 |
| 0001628280-25-022761 | 6 | 17 | EQ | 0 | H | Stock Issued During Period Value Acquisitions | us-gaap/2024 | Stock Issued During Period, Value, Acquisitions | 0 |
| 0001628280-25-022761 | 6 | 18 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001628280-25-022761 | 6 | 19 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Total other comprehensive (loss) income | 0 |
| 0001628280-25-022761 | 6 | 20 | EQ | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022761 | 6 | 21 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001628280-25-022761 | 6 | 22 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Ending balance | 0 |
| 0001628280-25-022761 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022761 | 7 | 4 | CF | 0 | H | Depreciation And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001628280-25-022761 | 7 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001628280-25-022761 | 7 | 6 | CF | 0 | H | Gain Loss On Investments And Income Loss From Equity Method Investments | 0001628280-25-022761 | Loss on investments | 1 |
| 0001628280-25-022761 | 7 | 7 | CF | 0 | H | Fair Value Option Changes In Fair Value Gain Loss1 | us-gaap/2024 | Change in fair value of notes receivable | 1 |
| 0001628280-25-022761 | 7 | 8 | CF | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liabilities | 0 |
| 0001628280-25-022761 | 7 | 9 | CF | 0 | H | Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High | us-gaap/2024 | Change in fair value of contingent consideration | 1 |
| 0001628280-25-022761 | 7 | 10 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Non-cash lease expense | 0 |
| 0001628280-25-022761 | 7 | 11 | CF | 0 | H | Noncash In Process Research And Development | 0001628280-25-022761 | Non-cash in-process research and development | 0 |
| 0001628280-25-022761 | 7 | 12 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Other non-cash activity | 1 |
| 0001628280-25-022761 | 7 | 14 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Changes in operating assets and liabilities: | 1 |
| 0001628280-25-022761 | 7 | 15 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0001628280-25-022761 | 7 | 16 | CF | 0 | H | Increase Decrease Right Of Use Assets | 0001628280-25-022761 | Operating lease right-of-use assets | 1 |
| 0001628280-25-022761 | 7 | 17 | CF | 0 | H | Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | Other non-current assets | 1 |
| 0001628280-25-022761 | 7 | 18 | CF | 0 | H | Increase Decrease In Other Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable, accrued expenses and other current liabilities | 0 |
| 0001628280-25-022761 | 7 | 19 | CF | 0 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2024 | Accounts payable, accrued expenses and other current liabilities | 0 |
| 0001628280-25-022761 | 7 | 20 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease liabilities, current and non-current | 0 |
| 0001628280-25-022761 | 7 | 21 | CF | 0 | H | Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | Other non-current liabilities | 0 |
| 0001628280-25-022761 | 7 | 22 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001628280-25-022761 | 7 | 24 | CF | 0 | H | Payments To Acquire Available For Sale Securities Debt | us-gaap/2024 | Purchases of marketable debt securities | 1 |
| 0001628280-25-022761 | 7 | 25 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of property and equipment | 1 |
| 0001628280-25-022761 | 7 | 26 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Business acquisition | 1 |
| 0001628280-25-022761 | 7 | 27 | CF | 0 | H | Payments For Proceeds From Other Investing Activities | us-gaap/2024 | Other | 1 |
| 0001628280-25-022761 | 7 | 28 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0001628280-25-022761 | 7 | 30 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from exercise of stock options | 0 |
| 0001628280-25-022761 | 7 | 31 | CF | 0 | H | Finance Lease Principal Payments | us-gaap/2024 | Principal payments on finance leases | 1 |
| 0001628280-25-022761 | 7 | 32 | CF | 0 | H | Payment For Contingent Consideration Liability Financing Activities | us-gaap/2024 | Contingent consideration payment | 1 |
| 0001628280-25-022761 | 7 | 33 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used in financing activities | 0 |
| 0001628280-25-022761 | 7 | 34 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effect of foreign exchange rates on cash and cash equivalents | 0 |
| 0001628280-25-022761 | 7 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash, cash equivalents and restricted cash | 0 |
| 0001628280-25-022761 | 7 | 36 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents, beginning of period | 0 |
| 0001628280-25-022761 | 7 | 37 | CF | 0 | H | Restricted Cash | us-gaap/2024 | Restricted cash, beginning of period | 0 |
| 0001628280-25-022761 | 7 | 38 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash, beginning of period | 0 |
| 0001628280-25-022761 | 7 | 39 | CF | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents, end of period | 0 |
| 0001628280-25-022761 | 7 | 40 | CF | 0 | H | Restricted Cash | us-gaap/2024 | Restricted cash, end of period | 0 |
| 0001628280-25-022761 | 7 | 41 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash, end of period | 0 |
| 0001628280-25-022761 | 8 | 6 | CF | 1 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable, from related parties | 1 |
| 0001628280-25-022761 | 8 | 7 | CF | 1 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2024 | Deferred revenue, current and non-current, from related parties | 0 |
| 0001628280-25-022761 | 4 | 30 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted (in shares) | 0 |
| 0001628280-25-022761 | 4 | 32 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0001628280-25-022761 | 4 | 34 | IS | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustment | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |